ARTICLE | Clinical News
Elagolix: Phase III data
January 12, 2015 8:00 AM UTC
Top-line data from the double-blind, North American Phase III M12-665 trial in 872 women ages 18-49 with moderate to severe endometriosis-associated pain showed that once-daily 150 mg elagolix and twi...